Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HNRNPLP2, or heterogeneous nuclear ribonucleoprotein L pseudogene 2, is annotated as a pseudogene on chromosome 15 (location 15q15) and does not encode a functional protein[5]. Pseudogenes are regions of DNA that resemble known genes but are typically non-functional due to mutations or lack of necessary regulatory elements. There is no evidence in the biomedical literature or genetic databases that HNRNPLP2 is expressed as a protein, functions as a therapeutic target, is involved in disease, or interacts with known drugs. It should not be confused with the functional gene heterogeneous nuclear ribonucleoprotein L (HNRNPL), which is an RNA-binding protein involved in mRNA processing and has recognized roles in health and disease[1][6]. The designation as a pseudogene means that this entry is not a valid therapeutic target in drug discovery or molecular medicine. In summary, HNRNPLP2 is a pseudogene with no known biological or pharmacological function and is not considered a drug target or disease-associated receptor/protein[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein L pseudogene 2 (HNRNPLP2).